Company intelligence / Profile preview

Eli Technologies

Indianapolis, Indiana, United Stateseli.build ↗

Ownership: Private
Employees: ~39000
Development stage: Other

Overview

Eli Lilly is one of the world’s largest pharmaceutical companies, with a $34.12 billion revenue in recent years. It has pioneered mass production of insulin, developed leading diabetes drugs like Humalog and Trulicity, blockbuster GLP‑1 agonists such as Mounjaro and Zepbound, as well as major psychiatric medications like Prozac. The company continues to expand its biotech capabilities through internal R&D investment and strategic acquisitions.

Therapeutic areas: PsychiatryEndocrinologyOncology
Modalities: Small moleculeMonoclonal antibodyPeptidesProteinmRNA-based drugs
Industry: Pharma

Partnerships

Cambrex for CDMO services under the Catalyze360 initiativeNumerous academic collaborations worldwide

Beyond the preview

Go deeper on Eli Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eli Technologies.

Explore the full profile